HRP20140191T1 - Spojevi [1,2,4]triazolo[1,5-a]piridina i [1,2,4]triazolo[1,5-c]pirimidina te njihova uporaba - Google Patents
Spojevi [1,2,4]triazolo[1,5-a]piridina i [1,2,4]triazolo[1,5-c]pirimidina te njihova uporaba Download PDFInfo
- Publication number
- HRP20140191T1 HRP20140191T1 HRP20140191AT HRP20140191T HRP20140191T1 HR P20140191 T1 HRP20140191 T1 HR P20140191T1 HR P20140191A T HRP20140191A T HR P20140191AT HR P20140191 T HRP20140191 T HR P20140191T HR P20140191 T1 HRP20140191 T1 HR P20140191T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- independently
- saturated aliphatic
- optionally substituted
- nhc
- Prior art date
Links
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 title 1
- QLOWGDIISXJREF-UHFFFAOYSA-N [1,2,4]triazolo[1,5-c]pyrimidine Chemical class C1=CN=CN2N=CN=C21 QLOWGDIISXJREF-UHFFFAOYSA-N 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 36
- -1 piperidino, piperazino, morpholino Chemical group 0.000 claims 35
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 7
- 101000586092 Homo sapiens Olfactory receptor 1C1 Proteins 0.000 claims 6
- 101000982235 Homo sapiens Olfactory receptor 2C1 Proteins 0.000 claims 6
- 102100030028 Olfactory receptor 1C1 Human genes 0.000 claims 6
- 102100026700 Olfactory receptor 2C1 Human genes 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005488 carboaryl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- RMXNCOFVHXQVCR-UHFFFAOYSA-N 3-methoxy-n-(5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)propanamide Chemical compound N12N=C(NC(=O)CCOC)N=C2C=CC=C1C=1C=CSC=1 RMXNCOFVHXQVCR-UHFFFAOYSA-N 0.000 claims 2
- FUGPHEWEIXUSPC-UHFFFAOYSA-N 4-[2-(cyclopropanecarbonylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-n-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 FUGPHEWEIXUSPC-UHFFFAOYSA-N 0.000 claims 2
- UETQQTGJAVROHO-UHFFFAOYSA-N 4-[2-(cyclopropanecarbonylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-n-[2-(dimethylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)NCCN(C)C)=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 UETQQTGJAVROHO-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101001121109 Homo sapiens Olfactory receptor 2F1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- JRKHVXNRBFCPAP-UHFFFAOYSA-N N-[5-(4-hydroxy-3,5-dimethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)=C1 JRKHVXNRBFCPAP-UHFFFAOYSA-N 0.000 claims 2
- 102100026616 Olfactory receptor 2F1 Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- SJQFGNDHBJDHCC-UHFFFAOYSA-N n-(5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C1=CC=CC=C1 SJQFGNDHBJDHCC-UHFFFAOYSA-N 0.000 claims 2
- NGWHONDIRJJSSB-UHFFFAOYSA-N n-(5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclohexanecarboxamide Chemical compound C1CCCCC1C(=O)NC(=NN12)N=C1C=CC=C2C=1C=CSC=1 NGWHONDIRJJSSB-UHFFFAOYSA-N 0.000 claims 2
- MYINWRKWYLUOOY-UHFFFAOYSA-N n-[5-(3-chloro-4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1=C(Cl)C(F)=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 MYINWRKWYLUOOY-UHFFFAOYSA-N 0.000 claims 2
- PHBDHHUATHARRH-UHFFFAOYSA-N n-[5-(3-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound ClC1=CC=CC(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)=C1 PHBDHHUATHARRH-UHFFFAOYSA-N 0.000 claims 2
- SFOPSPAWHOOJNO-UHFFFAOYSA-N n-[5-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound FC1=CC=CC(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)=C1 SFOPSPAWHOOJNO-UHFFFAOYSA-N 0.000 claims 2
- FJFVPJPUNSPTCR-FMIVXFBMSA-N n-[5-[(e)-2-phenylethenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2\C=C\C1=CC=CC=C1 FJFVPJPUNSPTCR-FMIVXFBMSA-N 0.000 claims 2
- UHMJCYYEBUYQMD-UHFFFAOYSA-N n-[5-[2-(dimethylamino)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 UHMJCYYEBUYQMD-UHFFFAOYSA-N 0.000 claims 2
- HBZYXYXJDJIAMH-UHFFFAOYSA-N n-[5-[3-(methanesulfonamido)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)=C1 HBZYXYXJDJIAMH-UHFFFAOYSA-N 0.000 claims 2
- ZDEPPYHICDGWLF-UHFFFAOYSA-N n-[5-[3-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound FC(F)(F)OC1=CC=CC(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)=C1 ZDEPPYHICDGWLF-UHFFFAOYSA-N 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims 1
- CGQMLLPFGJJVGU-UHFFFAOYSA-N 3-cyclohexyl-N-[5-(4-hydroxy-3,5-dimethylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]propanamide Chemical compound CC1=C(O)C(C)=CC(C=2N3N=C(NC(=O)CCC4CCCCC4)N=C3C=CC=2)=C1 CGQMLLPFGJJVGU-UHFFFAOYSA-N 0.000 claims 1
- 101100255945 Arabidopsis thaliana RWA2 gene Proteins 0.000 claims 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- 102100028470 Nuclear receptor subfamily 2 group C member 1 Human genes 0.000 claims 1
- 102100028448 Nuclear receptor subfamily 2 group C member 2 Human genes 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PYESPAOQLVUCND-UHFFFAOYSA-N n-[5-(2,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 PYESPAOQLVUCND-UHFFFAOYSA-N 0.000 claims 1
- PFUHEDXCYMUYNJ-UHFFFAOYSA-N n-[5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC=CC2=NC(NC(=O)C3CC3)=NN12 PFUHEDXCYMUYNJ-UHFFFAOYSA-N 0.000 claims 1
- IJFQRELXBPLBBQ-UHFFFAOYSA-N n-[5-[4-(4-methylpiperazin-1-yl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)C=C1 IJFQRELXBPLBBQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 1
- 108091008744 testicular receptors 2 Proteins 0.000 claims 1
- 108091008743 testicular receptors 4 Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (29)
1. Spoj, naznačen time, da je odabran između spojeva sa sljedećom formulom, te njegove farmaceutski prihvatljive soli, njegovi hidrati i solvati:
[image]
u kojoj:
- X= je neovisno -CR6=;
- R5 je neovisno -R5A;
- R6 je neovisno -R6A;
- R7 je neovisno -R7A;
- R8 je neovisno -R8A;
- W je neovisno -WA; i
- WAje neovisno -RWA1;
gdje:
- R5A je neovisno -Q5A;
- Q5Aje neovisno -R2A7 ili -R2A8;
- R6A je neovisno -H;
- R7A je neovisno -H;
- R8A je neovisno -H;
-RWA1 je neovisno –R1A7 ili –R1A8;
gdje:
- R1A7 je neovisno fenil; i
- R1A8je neovisno furanil, tienil, piridil ili pirimidinil;
gdje:
-R1A7 i –R1A8 su opcijski supstituiram s jednim ili više supstituenata –R1B1 i/ili s jednim ili više supstituenata –R1B2
gdje:
svaki –R1B1 je neovisno sljedeći:
-r1D1, -r1D2, -r1D3, -r1D4, -r1D5, -r1D6, -r1D7, -r1D8,
-l1D-R1D4, -l1D-R1D5, -l1D-R1D6, -L1D-R1D7 ili –L1D-R1D8;
svaki –R1B2 je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L1C-OH, -O-L1C-OH,
-OR1C1, -L1C-OR1C1, -O-L1C-OR1C1,
-SH, -SR1C1,
-CN,
-NO2,
-NH2, -NHR1C1, -NR1C12, -NR1C2R1C3;
-L1c-NH2; -L1c-NHR1C1, -L1C-NR1C12, -L1C-NR1C2R1C3,
-O-L1C-NH2, -O-L1C-NHR1C1, -O-L1C-NR1C12, -O-L1C-NR1C2R1C3,
-C(=O)OH, -C(=O)OR1C1,
-C(=O)R1C1,
-C(=O)NH2, -C(=O)NHR1C1, -C(=O)NR1C12, -C(=O)NR1C2R1C3,
-NHC(=O)R1C1, -NR1C1C(=O)R1C1,
-NHC(=O)OR1C1, -NR1C1C(=O)OR1C1,
-OC(=O)NH2, -OC(=O)NHR1C1, -OC(=O)NR1C12, -OC(=O)NR1C2R1C3,
-NHC(=O)NH2, -NHC(=O)NHR1C1,
-NHC(-O)NR1C12, -NHC(=O)NR1C2R1C3,
-NR1C1C(=O)NH2, -NR1C1C(=O)NHR1C1,
-NR1C1C(=O)NR1C12, -NR1C1C(=O)NR1C2R1C3,
-NHS(=O)2R1C1, -NR1C1S(=O)2R1C1,
-S(=O)2NH2, -S(=O)2NHR1C1. -s(=O)2NR1C12) -S(=O)2NR1C2R1C3,
-S(=O)R1C1, -S(=O)2R1C1, -OS(=O)2R1C1 ili -S(=O)2OR1C1;
gdje:
svaki –L1C- je neovisno zasićeni alifatski C1-5alkilen;
svaki –NR1C2R1C3 je neovisno azetidin, pirolidin, imidazolidin, pirazolidin, piperidin, piperazin, morfolin, azepin ili diazepin, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenih alifatskih C1-3alkila, -F i -CF3;
svaki-R1C1 je neovisno sljedeći:
-R1D1, -R1D2,-R1D3, -R1D4, -R1D5, -R1D6, -R1D7, -R1D8,
-L1DR1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7 ili –l1D-R1D8;
svaki –R1D1 je neovisno zasićeni alifatski C1-6alkil;
svaki –R1D2 je neovisno alifatski C2-6alkenil; svaki –R1D3je neovisno alifatski C2-6alkinil;
svaki –R1D3 je neovisno zasićeni C3-6cikloalkil;
svaki -R1D5 je neovisno C3-6cikloalkenil;
svaki –R1D6 je neovisno ne-aromatski C3-8heterociklil;
svaki –R1D7 je neovisno C6-10karboaril;
svaki –R1D8 je neovisno C5-10heteroaril;
svaki –L1D je neovisno zasićeni alifatski C1-3alkilen;
gdje:
svaki od –R1D4,-R1D5, -R1D6, -R1D7 i -R1D8 je opcijski supstituiran s jednim ili više supstituenata –R1B1 i/ili s jednim ili više supstituenata-R1B2;
svaki od –R1D1, -R1D2, -R1D3 i –L1D je opcijski supstituiran s jednim ili vise supstituenata
gdje:
svaki –R1B1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –R1B2 je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L1F-OH, -O-L1F-OH,
-OR1F1-L1F-OR1F1, -O-L1F-OR1F1,
-SH, -SR1F1,
-CN,
-NO2,
-NH2, -NHR1F1-NR1F12, -NR1F2R1F3,
-L1F-NH2, -L1F-NHR1F1, -L1F-NR1F,2, -L1F-NR1F2R1F3,
-C(=O)OH, -C(=O)OR1H,
-C(=O)NH2, -C(=O)NHR1F1, -C(=O)NR1F12 ili -C(=O)NR1F2R1F3;
gdje:
svaki –R1F1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –L1F-je neovisno zasićeni alifatski C1-3alkilen; i
svaki –NR1F2R1F3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino, azepino ili diazepino. i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3;
gdje:
-R2A7 je neovisno fenil ili naftil; i
-R2A8 je neovisno furanil, tienil, pirazolil, piridil, pirimidinil, 2,3-dihidro-benzofuranil, benzo[1,3]dioksolil, 2,3-dihidro-benzo[1,4]dioksinil, 3,4-dihidro-2H-benzo[b][1,4]dioksepinil ili 3,4-dihidro-2H-benzo[1,4]oksazinil;
gdje:
-R2A7 i –R2A8 su opcijski supstituirani s jednim ili vise supstituenata -R2B1 i/ili s jednim ili više supstituenata –R2B2;
gdje:
svaki –R2B1 je neovisno sljedeći:
-R2D1, -R2D2, -R2D3, -R2D4, -R2D5, -R2D6, -R2D7, -R2D8
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7 ili -L2D-R2D8;
svaki -R je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L2C–OH, -O-L2C-OH,
-OR2C1, -L2C-OR2C1, -O-L2C-OR2C1,
-SH, -SR2C1,
-CN,
-NO2;
-NH2, -NHR2C1, -NR2C12, -NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
-O-L2C-NH2, -O-L2C-NHR2C1, -O-L2C-NR2C12, -O-L2C-NR2C2R2C3,
-C(=O)OH, -C(=O)OR2C1,
-C(=O)R2C1,
-C(=O)NH2, -C(=O)NHR2C1, -C(=O)NR2C12, -C(=O)NR2C2R2C3,
-NHC(=O)R2C1, -NR2C1C(=O)R2C1,
-NHC(=O)OR2C1, -NR2C1C(=O)OR2C1,
-OC(=O)NH2, -OC(=O)NHR2C1, -OC(=O)NR2C12, -OC(=O)NR2C2R2C3,
-NHC(=O)NH2, -NHC(=O)NHR2C1,
-NHC(=O)NR2C1, -NHC(=O)NR2C2R2C3,
-NR2C1C(=O)NH2, -NR2C1C(=O)NHR2C1,
-NR2C1C(=O)NR2C12, -NR2C1C(=O)NR2C2R2C3,
-NHS(=O)2R2C1, -NR2C1S(=O)2R2C1,
-S(=O)2NH2, -S(=O)2NHR2C1, -S(=O)2NR2C12, -S(=O)2NR2C2R2C3,
-S(=O)R2C1, -S(=O)2R2C1, -OS(=O)2R2C1 ili -S(=O)2OR2C1;
gdje:
svaki –L2C- je neovisno zasićeni alifatski C1-5alkilen;
svaki –NR2C2R2C3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino. azepino ili diazepino, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenih alifatskih C1-3alkila, -F i -CF3;
svaki –R2C1 je neovisno sljedeći:
-R2D1, -R2D2, -R2D3, -R2D4 -R2D5, -R2D6, -R2D7, -R2D8,
-L2D-R2D4, -L2D-R2D5. -L2D-R2D6, -L2D-R2D7 ili -L2D-R2D8;
svaki –R2D1 je neovisno zasićeni alifatski C1-6alkil;
svaki –R2D2 je neovisno alifatski C2-6alkenil;
svaki –R2D3je neovisno alifatski C2-6lkinil;
svaki –R2D4 je neovisno zasićeni C3-6cikloalkil;
svaki -R2D5 je neovisno C3-6cikloalkenil;
svaki –R2D6 je neovisno ne-aromatski C3-8heterocildil;
svaki –R2D7 je neovisno C6-10karboaril;
svaki –R2D8 je neovisno C5-10eteroaril;
svaki –L2D- je neovisno zasićeni alifatski C1-3alkilen;
gdje:
svaki od –R2D4, -R2D5,-R2D6, -R2D7 i -R2D8 je opcijski supstituiran s jednim ili više supstituenata –R2E1 s jednim ili više supstituenata –R2E2;
svaki od –R2D1, -R2D2, -R2D3 i –L2D je opcijski supstituiran s jednim ili vise supstituenata –R2E2; i
gdje:
svaki -R2E1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –R2E2 je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3j
-OH, -L2F-OH, -O-L2F-OH,
-OR2F1, -L2F-OR2F1, -O-L2F-OR2F1,
-SH, -SR2F1,
-CN,
-NO2,
-NH2, -NHR2F1, -NR2F12, -NR2F2R2F3,
-L2F-NH2, -L2F-NHR2F1, -L2F-NR2F12, -L2F-NR2F2R2F3,
-C(=O)OH, -C(=O)OR2F1,
-C(=O)NH2, -C(=O)NHR2F1, -C(=O)NR2F12 ili -C(=O)NR2F2R2F3;
gdje:
svaki –R2F1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –L2F-je neovisno zasićeni alifatski C1-5alkilen; i
svaki –NR2F2R2F3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino, azepino ili diazepino i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3.
2. Spoj prema zahtjevu 1, naznačen time, da –RWA1 je neovisno –R1A7.
3. Spoj prema zahtjevu 1, naznačen time, da –RWA1 je neovisno –R1A8.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da -Q5Aje neovisno –R2A7.
5. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da –Q5Aje neovisno -R2A8.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da ako je prisutan –R1A7, tada je on neovisno odabran iz skupina sa sljedećim formulama, pri čemu svaki –R1X je neovisno –R1B1 ili –R1B2:
[image]
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da ako je prisutan –R1A8, tada je on neovisno odabran iz skupina sa sljedećim formulama, pri čemu svaki –R1X je neovisno –R1B1 ili –R1B2:
[image]
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time, da ako je prisutan –R2A7, tada je on neovisno odabran iz skupina sa sljedećim formulama, pri čemu svaki –R2X je neovisno –R2B1 ili –R2B2:
[image]
9. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da ako je prisutan –R2A8, tada je on neovisno odabran iz skupina sa sljedećom formulom, pri čemu svaki –R2X je neovisno -R2B1 ili -R2B2:
[image]
10. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da ako je prisutan –R2A8, tada je on neovisno 2,3-dihidro-benzo[1,4]dioksin-6-il, i opcijski je supstituiran.
11. Spoj, naznačen time, da je odabran između spojeva sa sljedećom formulom, te njegove farmaceutski prihvatljive soli, njegovi hidrati i solvati:
[image]
u kojoj:
-X= je neovisno –CR6=;
-R5 je neovisno –R5A;
-R6 je neovisno –R6A;
-R7 je neovisno –R7A;
-R8 je neovisno –R8A;
-W je neovisno –WA; i
-WAje neovisno -C(=O)RWA2;
gdje:
-R5A je neovisno –Q5A;
-Q5A je neovisno –R2A7, -R2A8 ili –NHR2C1;
-R6A je neovisno -H;
-R7A je neovisno -H;
-R8A je neovisno -H;
-RWA2 je neovisno –R1A1, -R1A4 ili –L1A-R1A4;
gdje:
-R1A1 je neovisno zasićeni alifatski C1-6alkil;
svaki –R1A4 je neovisno zasićeni C3-6cikloalkil;
-L1A-je neovisno zasićeni alifatski C1-3alkilen;
gdje:
svaki –R1A4 je opcijski supstituiran s jednim ili više supstituenata –R1B1 i/ili s jednim ili više supstituenata –R1B2; i
svaki od –R1A1 i –L1A-je opcijski supstituiran s jednim ili više supstituenata –R1B2;
gdje:
svaki –R1b1 je neovisno sljedeći:
-R1D1, R1D2, -R1D3, -R1D4, -R1D5, -R1D6, -R1D7, -R1D8,
-L1DR1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7 ili –L1D-R1D8;
svaki –R1B2 je neovisno:
-F, -Cl, -Br, -I,
-CF3,-OCF3,
-OH, -L1C-OH, -O-L1C-OH,
-OR1C1, -L1C-OR1C1, -O-L1C-OR1C1,
-SH, -SR1C1,
-CN,
-NO2,
-NH2, -NHR1C1, -NR1C12, -NR1C2R1C3,
-L1C-NH2, -L1C-NHR1C1, -L1C-NR1C12, -L1C-NR1C2R1C3,
-O-L1C-NH2, -O-L1C-NHR1C1, -O-L1C-NR1C12, -O-L1C-NR1C2 R1C3,
-C(=O)OH, -C(=O)OR1C1,
-C(=O)R1C1,
-C(=O)NH2, -C(=O)NHR1C1, -C(=O)NR1C12, -C(=O)NR1C2R1C3,
-NHC(=O)R1C1, -NR1C1C(=O)R1C1,
-NHC(=O)OR1C1, -NR1C1C(=O)OR1C1,
-OC(=O)NH2, -OC(=O)NHR1C1, -OC(=O)NR1C12, -OC(=O)NR1C2R1C3,
-NHC(=O)NH2, -NHC(-O)NHR1C1,
-NHC(=O)NR1C12,-NHC(=O)NR1C2R1C3,
-NR1C1C(=O)NH2,-NR1C1C(=O)NHR1C1,
-NR1C1C(=O)NR1C12, -NR1C1C(=O)NR1C2R1C3,
-NHS(=O)2R1IC1, -NR1C1S(=O)2R1C1,
-S(=O)2NH2, -S(=O)2NHR1C1, -S(=O)2NR1C12, -S(=O)2NR1C2R1C3,
-S(=O)R1C1, -S(=O)2R1C1, -OS(=O)2R1C1 ili -S(=O)2OR1C1;
gdje
svaki –L1C-je neovisno zasićeni alifatski C1-5alkilen;
svaki -NR1C2R1C3je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino, azepino ili diazepino, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenih alifatskih C1-3alkila, -F i –CF3;
svaki –R1C1 je neovisno:
-R1D1, -R1D2,-R1D3, -R1D4, -R1D5, R1D6, -R1D7, -R1D8,
-L1D-R1D4, -L1D-R1D5, -L1D-R1D6, -L1D-R1D7 ili –L1D-R1D8
svaki –R1D1 je neovisno zasićeni alifatski C1-6alkil;
svaki –R1D2 je neovisno alifatski C2-6alkenil;
svaki –R1D3 je neovisno alifatski C2-6alkinil;
svaki –R1D4 je neovisno zasićeni C3-6cikloalkil;
svaki –R1D5 je neovisno C3-6cikloalkenil;
svaki -R1D6je neovisno ne-aromatski C3-8heterociklil;
svaki -R1D7 je neovisno C6-10karboaril;
svaki –R1D8 je neovisno C5-10heteroaril;
svaki –L1D-je neovisno zasićeni alifatski C1-3alkilen;
gdje:
svaki od –R1D4, -R1D5, -R1D6, -R1D7 i –R1D8 je opcijski supstituiran s jednim ili više supstituenata –R1E1 i/ili s jednim ili više supstituenata –R1E2,
svaki od –R1D1, -R1D2, -R1D3 i-L1D- je opcijski supstituiran s jednim ili vise supstituenata-R1E2, i
gdje:
svaki –R1E1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –R1E2 je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L1F-OH, -O-L1F-OH,
-OR1F1 –L1F-OR1F1, -O-L1F-OR1F1,
-SH, -SR1F,,
-CN,
-NO2,
-NH2, -NHR1F1, -NR1F12, -NR1F2R1F3,
-L1F-NH2, -L1F-NHR1F1, -L1F-NR1F12, -L1F-NR1F2R1F3,
-C(=O)OH, -C(=O)OR1F1I;
-C(=O)NH2,-C(=O)NHR1F1, -C(=O)NR1F12 ili-C(=O)NR1F2R1F3;
gdje:
svaki –R1F1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –L1F- je neovisno zasićeni alifatski C1-5alkilen; i
svaki –NR1F2R1F3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino, azepino ili diazepino, i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3;
gdje:
-R2A7 je neovisno fenil ili naftil; i
-R2A8je neovisno furanil, tienil, pirazolil, piridil, pirimidinil, 2,3-dihidro-benzofuranil, benzo[1,3]dioksolil, 2,3-dihidro-benzo[1,4]dioksinil, 3,4-dihidro-2H-benzo[b][ 1,4]dioksepinil, ili 3,4-diliidro-2H-benzo[1,4]oksazinil;
gdje:
- R2A7 i -R2A8 su opcijski supstituirani s jednim ili više supstituenata -R2B1 i/ili s jednim ili više supstituenata –R2B2
gdje:
svaki –R2B1 je neovisno sljedeći:
R2D1, -R2D2, R2D3, -R2D4, -R2D5, -R2D6, -R2D7, -R2D8,
-L2D-R2D4, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7 ili -L2D-R2D8;
svaki –R2B2 je neovisno sljedeću
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L2C-OH, -O-L2C-OH,
-OR2C1, -L2C-OR2C1, -O-L2C-OR2C1,
-SH, -SR2C1,
-CN,
-NO2,
-NH2, -NHR2C1, -NR2C12, -NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
-O-L2C-NH2, -O-L2C-NHR2C1, -O-L2C-NR2C12, -O-L2C-NR2C2R2C3,
-C(=O)OH, -C(=O)OR2C1,
-C(-O)R2C1,
-C(=O)NH2,-C(=O)NHR2C1, -C(=O)NR2C12, -C(=O)NR2C2 R2C3,
-NHC(=O)R2C1, -NR2C1C(=O)R2C1,
-NHC(=O)OR2C1, -NR2ClC(=O)OR2C1,
-OC(=O)NH2, -OC(=O)NHR2C1, -CC(=O)NR2C12, -OC(=O)NR2C2R+2C3,
-NHC(=O)NH2, -NHC(=O)NHR2C1,
-NHC(=O)NR2C12, -NHC(=O)NR2C2R2C3,
-NR2C1C(=O)NH2, -NR2C1C(=O)NHR2C1 ,
-NR2C1C(=O)NR2C12, -NR2C1C(=O)NR2C2R2C3,
-NHS(=O)2R2C1 ,-NR2C1S(=O)2R2C1,
-S(=O)2NH2, -S(=O)2NHR2C1, -S(=O)2NR2C12, -S(=O)2NR2C2R2C3,
-S(=O)R2C1, -S(=O)2R2C1, -OS(=O)2R2C1 ili -S(=O)2OR2C1;
gdje:
svaki –L2C- je neovisno zasićeni alifatski C1-5alkilen;
svaki –NR2C2R2C3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfolino, azepino ili diazepino, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenog alifatskog C1-3alkila, -F i –CF3;
svaki –R2C1 je neovisno sljedeći:
-R2D1, -R2D2, -R2D3, -R2D4, -R2D5, -R2D6, -R2D7, -R2D8,
-L2D-R2D1, -L2D-R2D5, -L2D-R2D6, -L2D-R2D7 ili -L2D-R2D8;
svaki –R2D1 je neovisno zasićeni alifatski C1-6alkil;
svaki –R2D2 je neovisno alifatski C2-6alkenil;
svaki -R2D3je neovisno alifatski C1-6alkinil;
svaki –R2D4 je neovisno zasićeni C3-6cikloalkil;
svaki –R2D5 je neovisno C3-6cikloalkenil;
svaki –R2D6 je neovisno ne-aromatski C3-8heterociklil;
svaki –R2D7je neovisno C6-10karboaril;
svaki –R2D8 je neovisno C5-10heteroaril;
svaki –L2D- je neovisno zasićeni alifatski C1-3alkilen;
gdje:
svaki od –R2D4, -R2D5, -R2D6, -R2D7 i –R2D8 je opcijski supstituiran s jednim ili vise supstituenata -R2E1 i/ili s jednim ili više supstituenata –R2E2,
svaki od-R2D1,-R2D2,-R2D3 i-L2D- je opcijski supstituiran s jednim ili vise supstituenata-R2E2, i
gdje:
svaki –R2E1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki-R2E2 je neovisno sljedeći:
-F, -Cl, -Br, -I,
-CF3, -OCF3,
-OH, -L2F-OH, -O-L2F-OH,
-OR2F1, -L2F-OR2F1, -O-L2F-OR2F1,
-SH, -SR2F1,
-CN,
-NO2,
-NH2, -NHR2F1, -NR2FI2, -NR2F2R2F3,
-L2F-NH2, -L2F-NHR2FI, -L2F-NR2F12, -L2F-NR2F2R2F3,
-C(=O)OH, -C(=O)OR2F1,
-C(=O)NH2, -C(=O)NHR2F1, -C(=O)NR2F12 ili -C(=O)NR2F2R2F3;
gdje:
svaki –R2F1 je neovisno zasićeni alifatski C1-4alkil, fenil ili benzil;
svaki –L2F-je neovisno zasićeni alifatski C1-5alkilen; i
svaki –NR2F2R2F3 je neovisno azetidino, pirolidino, imidazolidino, pirazolidino, piperidino, piperazino, morfoiino, azepino ili diazepino, i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3;
pod uvjetom da navedeni spoj nije spoj odabran od sljedećih spojeva:
ciklopropan-karboksilna kiselina-(5-fenil-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid (PP-001) (WW-001);
ciklopropan-karboksilna kiselina-[5-(3-acetilamino-fenil)-[1,2.4]triazolo[1,5-a]piridin-2-il]-amid (PP-002)(WW-002);
ciklopropan-karboksilna kiselina-{5-[4-(4-metil-piperazin-1-il)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amid (PP-003) (WW-003);
ciklopropan-karboksilna kiselina-[5-(3-kloro-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-004) (WW-004);
ciklopropan-karboksilna kiselina-[5-(4-metoksi-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-005)(WW-005);
ciklopropan-karboksilna kiselina-[5-(6-metoksi-piridin-3-il)-[1,2.4]triazolo[1,5-a]piridin-2-il]-amid (PP-006)(WW-006);
ciklopropan-karboksilna kiselina-[5-(3-fluoro-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-007) (WW-007);
ciklopropan-karboksilna kiselina-[5-(4-hidroksi-3,5-dimetil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-008) (WW-008);
4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(2-dimetilamino-etil)-benzamid (PP-009) (WW-009);
ciklopropan-karboksilna kiselina-[5-(2,4-dimetoksi-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-010)(WW-010);
ciklopropan-karboksilna kiselina-[5-(3-metansulfonilamino-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-011) (WW-011);
ciklopropan-karboksilna kiselina-[5-(2-dimetilamino-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-012);
ciklopropan-karboksilna kiselina-[5-(3-kloro-4-fluoro-fenil)-[1,2,4]triazolo[l,5-a]piridin-2-il]-amid (PP-013);
ciklopropan-karboksilna kiseIina-[5-(3-trifluorometoksi-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-014);
ciklopropan-karboksilna kiselina-[5-((E)-stiril)-[1,2,4]triazolo[1,5-a]piridin-2-il]-amid (PP-015);
ciklopropan-karboksilna kiselina-(5-tiofen-3-il-[1,2.4]triazolo[1,5-a]piridin-2-il)-amid (PP-01 6);
3-cikloheksil-N-[5-(4-hidroksi-3,5-dimetil-fenil)-[1,2,4]triazolo[1,5-a]piridin-2-il]-propionamid (PP-017);
cikloheksan-karboksilna kiselina-(5-tiofen-3-il-[1,2,4]triazolo[1,5-a]piridin-2-il)-amid (PP-018);
3-metoksi-N-(5-tiofen-3-il-[1,2,4]triazolo[1,5-a]piridin-2-il)-propionamid (PP-021);
4-[2-(ciklopropankarbonil-amino)-[1,2,4]triazolo[1,5-a]piridin-5-il]-N-(2-hidroksi-etil)-benzamid (PP-022); i
ciklopropan-karboksilna kiselina-(5-furan-3-il-[1,2,4]lriazolo[1,5-a]piridin-2-il)-amid (PP-023).
12. Spoj prema zahtjevu 11, naznačen time, da –RWA2 je neovisno –R1A1.
13. Spoj prema zahtjevu 11, naznačen time, da –RWA2 je neovisno –R1A4.
14. Spoj prema zahtjevu 11, naznačen time, da -RWA2 je neovisno –L1A-R1A4.
15. Spoj prema bilo kojem od zahtjeva 11 do 14, naznačen time, da –Q5A je neovisno -R2A7.
16. Spoj prema bilo kojem od zahtjeva 11 do 14, naznačen time, da –Q5A je neovisno-RA28.
17. Spoj prema bilo kojem od zahtjeva 11 do 14, naznačen time, da –Q5A je neovisno -NHR2C1,
18. Spoj prema bilo kojem od zahtjeva 11 do 17, naznačen time, da ako je –R1A4 prisutan, tada je on svaki neovisno zasićeni C3 cikloalkil.
19. Spoj prema bilo kojem od zahtjeva 11 do 18, naznačen time, da ako je prisutan –R2A7, tada je on neovisno odabran iz skupina sa sljedećim formulama, pri čemu svaki –R2X je neovisno –R2B1 ili –R2B2:
[image]
20. Spoj prema bilo kojem od zahtjeva 11 do 19, naznačen time, da ako je prisutan –R2A8, tada je on neovisno odabran iz skupina sa sljedećom formulom, pri čemu svaki –R2X je neovisno –R2B1 ili –R2B2:
[image]
21. Spoj prema bilo kojem od zahtjeva 11 do 19, naznačen time, da ako je prisutan –R2A8, tada je on neovisno 2,3-dihidro-benzo[1,4]dioksin-6-il, i opcijski je supstituiran.
22. Spoj prema bilo kojem od zahtjeva 11 do 21, naznačen time, da je
svaki –R1B1 neovisno sljedeći:
-R1D1, -R1D2, -R1D4, -R1D7, -R1D8, -L1D-R1D4, -L1D-R1D6, -L1D-R1D7 ili –L1D-R1D8;
svaki –R1B2 je neovisno sljedeći:
-F, -Cl,
-CF3, -OCF3,
-OH, -L1C-OH, -O-L1C-OH,
-OR1C1, -L1C-OR1C1, -O-L1C-OR1C1;
-SR1C1,
-CN,
-NO2,
-NH2, -NHR1C1, -NR1C12, -NR1C2R1C3,
-L1C-NH2, -L1C-NHR1C1, -L1C-NR1C12, -L1C-NR1C2R1C3,
-O-L1C-NH2, -O-L1C-NHR1C1, -O-L1C-NR1C12, -O-L1C-NR1C2R1C3,
-C(=O)R1C1,
-C(=O)NHR1C1, -C(=O)NR1C12, -C(=O)NR1C2RIC3,
-NHC(=O)R1C1, -NR1C1C(=O)R1C1,
-NHC(=O)NHR1C1,
-NHC(=O)NR1C12, -NHC(=O)NR1C2R1C3,
-NR1C1C(=O)NHR1C1,
-NR1C1(=O)NR1C12, -NR1C1C(=O)NR1C2R1C3,
-NHS(=O)2R1C1, -NR1C1S(=O)2R1C1,
-S(=O)2NHR1C1, -S(=O)2NR1C12, -S(=O)2NR1C2R1C3,
-S(=O)R1C1 ili -S(=O)2R1C1;
svaki –L1C je zasićeni alifatski C1-3alkilen;
svaki –NR1C2R1C3 je neovisno pirolidino, piperidino, piperazino ili morfolino, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenih alifatskih C1-3alkila, -F i -CF3;
svaki –R1C1 je neovisno sljedeći: -R1D1, -R1D2, -R1D3, -L1D-R1D7 ili –L1D-R1D8;
svaki -L1D-, ako je prisutan, tada je neovisno –CH2-;
svaki –R1D1, ako je prisutan, tada je neovisno zasićeni alifatski C1-3alkil;
svaki –R1D4, ako je prisutan, tada je neovisno zasićeni C5-6cikloalkil;
svaki -R1D6, ako je prisutan, tada je neovisno pirolidinil, piperidinil, piperazinil, morfolinil, tetrahidrofuranil, ili tetrahidropiranil, i opcijski je supstituiran;
svaki -R1D7, ako je prisutan, tada je neovisno fenil ili naftil, i opcijski je supstituiran;
svaki –R1D8, ako je prisutan, tada je neovisno furanil, tienil, pirolil, imidazolil, pirazolil, triazolil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridil, pirimidinil ili piridazinil, i opcijski je supstituiran; ili
svaki –R1D8, ako je prisutan, tada je neovisno benzofuranil, benzotienil, benzopirolil, benzoimidazolil, benzopirazolil, benzotriazolil, benzoksazolil, benzoizoksazolil, benzotiazolil, benzoizotiazolil, benzopiridil, benzopirimidinil ili benzopiridazinil, i opcijski je supstituiran;
svaki –R1E1 je neovisno zasićeni alifatski C1-4alkil;
svaki –R1E2 je neovisno sljedeći:
-F, -Cl,
-CF3, -OCF3,
-CN,
-OH, -O-L1F-OH, -O-L1F-OH
-OR1F1-L1F-OR1F1, -O-L1F-OR1F1,
-NH2, -NHR1F1, -NR1F12, -NR1F2R1F3,
-L1F-NH2, -L1F-NHR1F1, -L1F-NR1F12, -L1F-NR1F2R1F3,
-C(=O)NHR1F1, -C(=O)NR1F12 ili -C(=O)NR1F2R1F3;
svaki –R1F1 je neovisno zasićeni alifatski C1-4alkil;
svaki –L1F je zasićeni alifatski C1-3alkilen; i
svaki –NR1F2R1F3 je neovisno pirolidino, piperidino. piperazino, ili morfolino, i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3.
23. Spoj prema bilo kojem od zahtjeva 11 do 22, naznačen time, da je
svaki –R2B1 neovisno sljedeći:
-R2D1, -R2D2, -R2D4, -R2D7, -R2D8, -L2D-R2D4, -L2D-R2D7 ili –L2D-R2D8;
svaki –R2B2 je neovisno sljedeći:
-F, -Cl,
-CF3, -OCF3,
-OH, -L2C-OH, -O-L2C-OH,
-OR2C1, -L2C-OR2C1, -O-L2C-OR2C1,
-SR2C1
-CN,
-NO2,
-NH2, -NHR2C1, -NR2C12, -NR2C2R2C3,
-L2C-NH2, -L2C-NHR2C1, -L2C-NR2C12, -L2C-NR2C2R2C3,
-O-L2C-NH2, -O-L2C-NHR2C1, -O-L2C-NR2C12, -O-L2C-NR2C2R2C3,
-C(=O)R2C1,
-C(=O)NH2, -C(=O)NHR2C1, -C(=O)NR2C12, -C(=O)NR2C2R2C3,
-NHC(=O)R2C1, -NR2C1C(=O)R2C1,
-NHC(=O)NH2, -NHC(=O)NHR2C1,
-NHC(=O)NR2C12,-NHC(=O)NR2C2R2C3,
-NR2C1, C(-O)NH2, -NR2C1C(=O)NHR2C1,
-NR2C1C(=O)NR2C12, -NR2C1C(=O)NR2C2R2C3,
-NHS(=O)2R2C1, -NR2C1S(-O)2R2C1,
-S(=O)2NH2, -S(=O)2NHR2C1, -S(=O)2NR2C12, -S(=O)2NR2C2R2C3,
-S(=O)R2C1 ili -S(=O)2R2C1;
svaki –L2C je zasićeni alifatski C1-3alkilen;
svaki –NR2C2R2C3 je neovisno pirolidino, piperidino, piperazino ili morfolino, i opcijski je supstituiran s jednom ili više skupina odabranih od zasićenih alifatskih C1-3alkila, -F i -CF3;
svaki –R2C1 je neovisno sljedeći:
-R2D1, -R2D7, -R2D8, -L2D-R2D7 ili -L2D-R2D8;
svaki –L2D-, ako je prisutan, tada je neovisno -CH,-;
svaki –R2D1, ako je prisutan, tada je neovisno zasićeni alifatski C1-3alkil;
svaki –R2D4 ako je prisutan, tada je neovisno zasićeni C5-6cikloalkil;
svaki –R2D6, ako je prisutan, tada je neovisno pirolidinil, piperidinil, piperazinil, morfolinil, tetrahidrofuranil ili tetrahidropiranil, i opcijski je supstituiran;
svaki –R2D7, ako je prisutan, tada je neovisno fenil ili naftil, i opcijski je supstituiran;
svaki –R2D8, ako je prisutan, tada je neovisno furanil, tienil, pirolil, imidazolil, pirazolil, triazolil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridil, pirimidinil ili piridazinil, i opcijski je supstituiran; ili
svaki –R2D8, ako je prisutan, tada je neovisno benzofuranil, benzotienil, benzopirolil, benzoimidazolil, benzopirazolil, benzotriazolil, benzoksazolil, benzoizoksazolil, benzotiazolil, benzoizotiazolil, benzopiridil, benzopirimidinil ili benzopiridazinil, i opcijski je supstituiran;
svaki –R2E1 je neovisno zasićeni alifatski C1-4alkil;
svaki-R2E2 je neovisno sljedeći:
-F, -Cl,
-CF3, -OCF3,
-OH, -L2F-OH, -O-L2F-OH,
-OR2F1, -L2F-OR2F1, -O-L2F-OR2F1,
-CN,
-NH2, -NHR2F1, -NR2F12, -NR2F2R2F3,
-L2F-NH2, -L2F-NHR2F1, -L2F-NR2F,2, -L2F-NR2F2R2F3,
-C(=O)NHR2F1, -C(=O)NR2F12 ili -C(=O)NR2F2R2F3;
svaki –R2F1 je neovisno zasićeni alifatski C1-4alkil;
svaki –L2F je zasićeni alifatski C1-3alkilen; i
svaki –NR2F2R2F3 je neovisno pirolidino, piperidino, piperazino ili morfolino, i opcijski je supstituiran s jednom ili više skupina odabranih od C1-3alkila, -F i -CF3.
24. Spoj prema zahtjevu 1, naznačen time, da je odabran od sljedećih spojeva, te njegove farmaceutski prihvatljive soli, njegovi hidrati i solvati:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
25. Spoj prema zahtjevu 11, naznačen time, da je odabran od sljedećih spojeva, te njegove farmaceutski prihvatljive soli, njegovi hidrati i solvati:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
26. Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 25, te farmaceutski prihvatljiv nosač ili razrjeđivač.
27. Spoj prema bilo kojem od zahtjeva 1 do 25, naznačen time, da se upotrebljava u obradi ljudskog ili životinjskog tijela putem liječenja.
28. Spoj prema bilo kojem od zahtjeva 1 do 25, naznačen time, da se upotrebljava u postupku liječenja sljedećih stanja:
proliferativno stanje; ili rak; ili
rak čvrstog tumora; ili
rak tekućeg tumora; ili
hematološki rak; ili
rak debelog crijeva, gastrički rak, rak dojke, rak pluća, akutna mijeloidna leukemija, tiroidni rak, očni rak, rak prostate, rak očnog melanoma, rak jajnika, rak bubrega, rak kože ili karcinom rožnatih stanica.
29. Uporaba spoja prema bilo kojem od zahtjeva 1 do 25, naznačena time, da jeza proizvodnju lijeka za liječenje sljedećih stanja:
proliferativno stanje; ili
rak; ili
rak čvrstog tumora; ili rak tekućeg tumora; ili
hematološki rak; ili
rak debelog crijeva, gastrički rak, rak dojke, rak pluća, akutna mijeloidna leukemija, tiroidni rak, očni rak, rak prostate, rak očnog melanoma, rak jajnika, rak bubrega, rak kože ili karcinom rožnatih stanica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97879207P | 2007-10-10 | 2007-10-10 | |
GBGB0719803.9A GB0719803D0 (en) | 2007-10-10 | 2007-10-10 | Therapeutic compounds and their use |
PCT/GB2008/003428 WO2009047514A1 (en) | 2007-10-10 | 2008-10-10 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140191T1 true HRP20140191T1 (hr) | 2014-04-25 |
Family
ID=38787938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140191AT HRP20140191T1 (hr) | 2007-10-10 | 2014-03-03 | Spojevi [1,2,4]triazolo[1,5-a]piridina i [1,2,4]triazolo[1,5-c]pirimidina te njihova uporaba |
Country Status (11)
Country | Link |
---|---|
US (4) | US8431596B2 (hr) |
EP (1) | EP2217578B9 (hr) |
CY (1) | CY1114911T1 (hr) |
DK (1) | DK2217578T5 (hr) |
ES (1) | ES2446298T3 (hr) |
GB (1) | GB0719803D0 (hr) |
HR (1) | HRP20140191T1 (hr) |
PL (1) | PL2217578T3 (hr) |
PT (1) | PT2217578E (hr) |
SI (1) | SI2217578T1 (hr) |
WO (1) | WO2009047514A1 (hr) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174086A1 (en) | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP5595389B2 (ja) | 2008-06-20 | 2014-09-24 | ジェネンテック, インコーポレイテッド | トリアゾロピリジンjak阻害剤化合物と方法 |
JP5512665B2 (ja) * | 2008-06-20 | 2014-06-04 | ジェネンテック, インコーポレイテッド | トリアゾロピリジンjak阻害剤化合物と方法 |
WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010010189A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
AR073010A1 (es) * | 2008-08-12 | 2010-10-06 | Takeda Pharmaceutical | Compuesto amida con actividad agonista del gpr52 |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
AU2011211410B2 (en) * | 2009-02-13 | 2013-01-31 | Fovea Pharmaceuticals Sa | [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors |
CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
EP2438066A2 (en) * | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
AU2011258555B2 (en) | 2010-05-25 | 2015-01-22 | Dow Agrosciences Llc | Process for the preparation of 5-Substituted-8-alkoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-amines |
UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
TW201204723A (en) * | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
MX2013002198A (es) | 2010-08-27 | 2013-03-18 | Merck Patent Gmbh | Derivados de triazolopirazina. |
WO2012078574A2 (en) * | 2010-12-06 | 2012-06-14 | Cephalon, Inc. | Janus kinase 2 (jak2) inhibitor for the treatment of lupus |
AP3491A (en) * | 2011-04-21 | 2015-12-31 | Bayer Ip Gmbh | Triazolopyridines |
WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
PT2810937T (pt) | 2012-01-31 | 2017-03-03 | Daiichi Sankyo Co Ltd | Derivado de piridona |
KR20130091464A (ko) | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
WO2013162061A1 (ja) * | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
PE20150354A1 (es) | 2012-07-10 | 2015-03-21 | Bayer Pharma AG | Metodos para preparar triazolopiridinas sustituidas |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
WO2014198647A2 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Prodrug derivatives of substituted triazolopyridines |
AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
MX2016006815A (es) | 2013-11-27 | 2016-12-02 | Signalchem Lifesciences Corp | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
CN103965202B (zh) * | 2014-05-21 | 2016-01-20 | 邹宏丽 | 二环稠合杂环化合物、其制备方法及用途 |
WO2016004272A1 (en) * | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
TWI723572B (zh) * | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
UA118149C2 (uk) | 2015-01-20 | 2018-11-26 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор jak |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
EA036058B1 (ru) | 2015-04-29 | 2020-09-21 | Уси Форчун Фармасьютикал Ко., Лтд | Ингибитор jak |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
PL3305788T3 (pl) | 2015-05-29 | 2021-03-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Inhibitor kinazy janusowej |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
US10947239B2 (en) | 2015-11-02 | 2021-03-16 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
ES2896079T3 (es) | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
MX2018012901A (es) | 2016-04-22 | 2019-06-06 | Incyte Corp | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). |
CN106188041B (zh) * | 2016-06-29 | 2017-12-08 | 四川大学华西医院 | [1,2,4]三唑并[1,5‑a]吡啶衍生物 |
WO2018000549A1 (zh) * | 2016-06-29 | 2018-01-04 | 四川大学华西医院 | [1,2,4]三唑并[1,5-a]吡啶衍生物及其晶型 |
CN107759587B (zh) * | 2016-08-19 | 2021-01-26 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
CN107880038B (zh) * | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
AU2017350688B2 (en) * | 2016-10-26 | 2021-04-01 | Rapport Therapeutics, Inc. | Fused azaheterocyclic compounds and their use as AMPA receptor modulators |
CN109963851B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 融合的双环吡啶化合物及其作为ampa受体调节剂的用途 |
EA039788B1 (ru) | 2016-11-02 | 2022-03-14 | Янссен Фармацевтика Нв | Производные [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
ES2912264T3 (es) | 2016-11-02 | 2022-05-25 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
BR112019008163A2 (pt) | 2016-11-02 | 2019-07-09 | Janssen Pharmaceutica Nv | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 |
JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
MA53010A (fr) | 2018-06-29 | 2021-05-05 | Incyte Corp | Formulations d'un inhibiteur de axl/mer |
EP3818063A1 (en) | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
MX2021011548A (es) * | 2019-03-30 | 2021-10-22 | Unichem Lab Ltd | Proceso novedoso para la preparacion de filgotinib e intermediarios del mismo. |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
CA3138307A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
EP4011880A4 (en) * | 2019-08-06 | 2023-09-13 | Jiangsu Carephar Pharmaceutical Co., Ltd | JAK KINASE INHIBITOR AND USE THEREOF |
MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
WO2022007921A1 (zh) * | 2020-07-10 | 2022-01-13 | 北京范恩柯尔生物科技有限公司 | 三嗪类化合物及其组合物和用途 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN115819425A (zh) * | 2022-12-22 | 2023-03-21 | 五邑大学 | 一种三唑并六元氮杂环-2-胺类化合物及其制备方法和应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL105768C (hr) | 1959-02-25 | |||
US3053844A (en) | 1959-04-13 | 1962-09-11 | Ici Ltd | Mono-acyl derivatives of s-triazolo [2, 3-c] pyrimidines |
GB873223A (en) | 1959-04-13 | 1961-07-19 | Ici Ltd | Heterocyclic compounds |
GB897870A (en) | 1959-06-15 | 1962-05-30 | Ici Ltd | s-triazolo[2, 3-c]pyrimidine derivatives |
US3046276A (en) | 1959-06-15 | 1962-07-24 | Ici Ltd | S-triazolo-[2, 3-c] pyrimidine derivatives |
US2963480A (en) | 1959-12-29 | 1960-12-06 | Edward C Taylor | 6-pteridinehydrazine and amidrazone derivatives |
US4579848A (en) * | 1983-07-28 | 1986-04-01 | American Cyanamid Company | 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines |
NZ208996A (en) | 1983-07-28 | 1989-08-29 | American Cyanamid Co | 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions |
JPH04204441A (ja) | 1990-11-29 | 1992-07-24 | Konica Corp | 新規な染料を含有するハロゲン化銀写真感光材料 |
US5358950A (en) | 1991-07-05 | 1994-10-25 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists |
FR2678618B1 (fr) | 1991-07-05 | 1993-11-05 | Upsa Laboratoires | Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
DK0877745T3 (da) | 1996-09-24 | 2001-11-05 | Dow Agrosciences Llc | N-([1,2,4]triazoloazinyl)benzensulfonamid- og pyridinsulfonamidforbindelser og deres anvendelse som herbicider |
JPH10148903A (ja) | 1996-11-20 | 1998-06-02 | Konica Corp | 耐圧性の改良されたハロゲン化銀写真感光材料 |
US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
US6693116B2 (en) | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
JP2003213152A (ja) | 2002-01-23 | 2003-07-30 | Konica Corp | 着色組成物、着色微粒子分散物、インクジェット用インク及びインクジェット記録方法 |
NZ540791A (en) | 2003-02-13 | 2009-09-25 | Banyu Pharma Co Ltd | Novel 2-pyridinecarboxamide derivatives |
ES2264795T3 (es) * | 2003-02-14 | 2007-01-16 | Pfizer Products Inc. | Triazolo-piridinas como compuestos antiinflamatorios. |
WO2005012306A2 (en) | 2003-07-25 | 2005-02-10 | Neurogen Corporation | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands |
DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
WO2005018532A2 (en) | 2003-08-25 | 2005-03-03 | Actar Ab | Purine receptor binding compounds |
HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
JP4204441B2 (ja) | 2003-10-31 | 2009-01-07 | ゲイツ・ユニッタ・アジア株式会社 | 寿命予知可能なタイミングベルト及びその製造方法 |
US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
TW200638882A (en) | 2005-02-04 | 2006-11-16 | Senomyx Inc | Molecules comprising linked organic moieties as flavor modifiers for comestible compositions |
US7968703B2 (en) * | 2005-03-07 | 2011-06-28 | Shire Canada Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
SG174086A1 (en) * | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
EP1894931A1 (en) | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
CA2691448A1 (en) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP5595389B2 (ja) | 2008-06-20 | 2014-09-24 | ジェネンテック, インコーポレイテッド | トリアゾロピリジンjak阻害剤化合物と方法 |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
-
2007
- 2007-10-10 GB GBGB0719803.9A patent/GB0719803D0/en not_active Ceased
-
2008
- 2008-10-10 WO PCT/GB2008/003428 patent/WO2009047514A1/en active Application Filing
- 2008-10-10 US US12/679,871 patent/US8431596B2/en active Active
- 2008-10-10 PT PT88065651T patent/PT2217578E/pt unknown
- 2008-10-10 EP EP08806565.1A patent/EP2217578B9/en not_active Revoked
- 2008-10-10 DK DK08806565.1T patent/DK2217578T5/da active
- 2008-10-10 PL PL08806565T patent/PL2217578T3/pl unknown
- 2008-10-10 ES ES08806565.1T patent/ES2446298T3/es active Active
- 2008-10-10 SI SI200831148T patent/SI2217578T1/sl unknown
-
2013
- 2013-04-24 US US13/869,374 patent/US9012633B2/en active Active
-
2014
- 2014-02-24 CY CY20141100147T patent/CY1114911T1/el unknown
- 2014-03-03 HR HRP20140191AT patent/HRP20140191T1/hr unknown
-
2015
- 2015-03-16 US US14/658,437 patent/US9394301B2/en active Active
-
2016
- 2016-06-20 US US15/186,689 patent/US9771362B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170066762A1 (en) | 2017-03-09 |
EP2217578B9 (en) | 2014-09-10 |
DK2217578T3 (da) | 2014-02-03 |
PL2217578T3 (pl) | 2014-05-30 |
EP2217578B1 (en) | 2013-12-04 |
WO2009047514A1 (en) | 2009-04-16 |
US9394301B2 (en) | 2016-07-19 |
US20100298339A1 (en) | 2010-11-25 |
EP2217578A1 (en) | 2010-08-18 |
SI2217578T1 (sl) | 2014-03-31 |
US9771362B2 (en) | 2017-09-26 |
US9012633B2 (en) | 2015-04-21 |
PT2217578E (pt) | 2014-02-17 |
US20140155594A1 (en) | 2014-06-05 |
US8431596B2 (en) | 2013-04-30 |
US20150246915A1 (en) | 2015-09-03 |
CY1114911T1 (el) | 2016-12-14 |
ES2446298T3 (es) | 2014-03-07 |
DK2217578T5 (da) | 2014-11-10 |
ES2446298T9 (es) | 2014-09-29 |
GB0719803D0 (en) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140191T1 (hr) | Spojevi [1,2,4]triazolo[1,5-a]piridina i [1,2,4]triazolo[1,5-c]pirimidina te njihova uporaba | |
JP6594570B2 (ja) | ピルビン酸キナーゼ(pkr)活性化剤としてのピロロピロール組成物 | |
CA2599124C (en) | Imidazo (1,2-a) pyridine compounds as vegf-r2 inhibitors | |
AU2019249849A1 (en) | BRM targeting compounds and associated methods of use | |
CN101668757A (zh) | 作为激酶调节剂的吡咯并[2,3-b]吡啶衍生物 | |
AR076928A1 (es) | Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres. | |
BRPI0619146A2 (pt) | derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis | |
EP3498693A1 (en) | Heterocyclic compound | |
HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
CN103958506A (zh) | 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 | |
JP2012525335A5 (hr) | ||
RU2007133655A (ru) | Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а | |
JP2011529504A5 (hr) | ||
BR112012006802A2 (pt) | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção | |
JP2013522286A5 (hr) | ||
ES2778200T3 (es) | Derivado de sulfonamida y su uso medicinal | |
SG175001A1 (en) | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives | |
JP2007521287A5 (hr) | ||
AR054191A1 (es) | Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina | |
CN101405278A (zh) | 新颖的杂环NF-κB抑制剂 | |
NZ510629A (en) | [1,2,4]Triazolo[1,5-c]pyrimidine derivatives and pharmaceutical use as adenosine A2A receptor antagonists | |
JP2013515032A5 (hr) | ||
EP2986300A2 (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
JP2016527184A (ja) | Slc2a輸送体阻害剤 | |
ES2689325T3 (es) | Derivados de carbamoilo de carbonilamino-pirazoles bicíclicos como pro-fármacos |